Usefulness of somatosensory evoked potentials for monitoring the clinical course of patients with chronic inflammatory demyelinating polyradiculoneuropathy.

Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 7803146 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4598 (Electronic) Linking ISSN: 0148639X NLM ISO Abbreviation: Muscle Nerve Subsets: MEDLINE

Publication: <2005-> : Hoboken, NJ : John Wiley & Sons
Original Publication: New York, NY : John Wiley & Sons

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*/physiopathology ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*/diagnosis ; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating*/therapy ; Evoked Potentials, Somatosensory*/physiology; Humans ; Male ; Female ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Neural Conduction/physiology

Introduction/aims: Somatosensory evoked potentials (SSEPs) are described as a supportive tool to diagnose chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); however, there is a lack of studies determining the effectiveness of SSEPs in monitoring the clinical course of individuals with this condition. The aims of this study are to evaluate the utility of SSEPs in monitoring patients with CIDP and to assess their association with clinical outcomes following immunomodulatory therapy.
Methods: This was a single-center retrospective observational study that included patients who met European Federation of Neurological Societies and Peripheral Nerve Society criteria for CIDP between 2018 and 2023. SSEPs were performed at diagnosis and during follow-up after the start of immunomodulatory treatment. Fisher's exact test was employed to assess the association between clinical improvement and SSEP improvement.
Results: Eighteen patients were included in the study. Ten patients had a typical CIDP pattern and 11 were male. In 17, SSEPs were abnormal prior to the start of immunomodulatory treatment. In patients who showed clinical improvement with immunomodulatory therapy, we observed that 15/17 had partial or complete improvement in SSEPs. Patients who showed no clinical improvement with first-line treatment exhibited worsening SSEPs. There was a significant association between clinical and SSEPs improvement (p = 0.009).
Discussion: We observed a positive association between improvement in SSEPs and clinical improvement in patients with CIDP. Our data suggest that SSEPs may be useful for monitoring the clinical course of patients with CIDP, but additional, larger studies are needed.
(© 2024 Wiley Periodicals LLC.)

Bunschoten C, Jacobs BC, Van den Bergh PYK, Cornblath DR, van Doorn PA. Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Lancet Neurol. 2019;18:784‐794. doi:10.1016/S1474‐4422(19)30144‐9.
Querol L, Devaux J, Rojas‐Garcia R, Illa I. Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications. Nat Rev Neurol. 2017;13:533‐547. doi:10.1038/NRNEUROL.2017.84.
Allen JA, Merkies ISJ, Lewis RA. Monitoring clinical course and treatment response in chronic inflammatory demyelinating polyneuropathy during routine care: a review of clinical and laboratory assessment measures. JAMA Neurol. 2020;77:1159‐1166. doi:10.1001/JAMANEUROL.2020.0781.
Allen JA, Eftimov F, Querol L. Outcome measures and biomarkers in chronic inflammatory demyelinating polyradiculoneuropathy: from research to clinical practice. Expert Rev Neurother. 2021;21:805‐816. doi:10.1080/14737175.2021.1944104.
Yiannikas C, Vucic S. Utility of somatosensory evoked potentials in chronic acquired demyelinating neuropathy. Muscle Nerve. 2008;38:1447‐1454. doi:10.1002/MUS.21078.
Tsukamoto H, Sonoo M, Shimizu T. Segmental evaluation of the peripheral nerve using tibial nerve SEPs for the diagnosis of CIDP. Clin Neurophysiol. 2010;121:77‐84. doi:10.1016/J.CLINPH.2009.09.019.
Salhi H, Corcia P, Remer S, Praline J. Somatosensory evoked potentials in chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Neurophysiol. 2014;31:241‐245. doi:10.1097/WNP.0000000000000050.
Devic P, Petiot P, Mauguiere F. Diagnostic utility of somatosensory evoked potentials in chronic polyradiculopathy without electrodiagnostic signs of peripheral demyelination. Muscle Nerve. 2016;53:78‐83. doi:10.1002/MUS.24693.
Ayrignac X, Viala K, Koutlidis RM, et al. Sensory chronic inflammatory demyelinating polyneuropathy: an under‐recognized entity? Muscle Nerve. 2013;48:727‐732. doi:10.1002/MUS.23821.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al. European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force‐second revision. Eur J Neurol. 2021;28:3556‐3583. doi:10.1111/ENE.14959.
Hughes R, MedSci F, Bensa S, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 2001;50:195‐201. doi:10.1002/ANA.1088.
Van Nes SI, Vanhoutte EK, Van Doorn PA, et al. Rasch‐built Overall Disability Scale (R‐ODS) for immune‐mediated peripheral neuropathies. Neurology. 2011;76:337‐345. doi:10.1212/WNL.0B013E318208824B.
Draak TH, Pruppers MH, van Nes SI, et al. Grip strength comparison in immune‐mediated neuropathies: Vigorimeter vs. Jamar. J Peripher Nerv Syst. 2015;20:269‐276. doi:10.1111/JNS.12126.
Vanhoutte EK, Latov N, Deng C, et al. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG—the ICE study. Eur J Neurol. 2013;20:748‐755. doi:10.1111/J.1468‐1331.2012.03851.X.
Vanhoutte EK, Faber CG, Van Nes SI, et al. Modifying the Medical Research Council grading system through Rasch analyses. Brain. 2012;135:1639‐1649. doi:10.1093/BRAIN/AWR318.
Gorson KC, Van Schaik IN, Merkies ISJ, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst. 2010;15:326‐333. doi:10.1111/J.1529‐8027.2010.00284.X.
Caporale CM, Staedler C, Gobbi C, Bassetti CL, Uncini A. Chronic inflammatory lumbosacral polyradiculopathy: a regional variant of CIDP. Muscle Nerve. 2011;44:833‐837. doi:10.1002/MUS.22165.
Clerici AM, Nobile‐Orazio E, Mauri M, Squellati FS, Bono GG. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long‐lasting case of chronic immune sensory polyradiculopathy. BMC Neurol. 2017;17:17. doi:10.1186/S12883‐017‐0906‐2.
Thirouin J, Petiot P, Antoine JC, et al. Usefulness and prognostic value of diagnostic tests in patients with possible chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve. 2022;66:304‐311. doi:10.1002/MUS.27655.
Goedee HS, van der Pol WL, van Asseldonk JH, et al. Diagnostic value of sonography in treatment‐naive chronic inflammatory neuropathies. Neurology. 2017;88:143‐151. doi:10.1212/WNL.0000000000003483.
Liberatore G, Manganelli F, Cocito D, et al. Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: data from the Italian CIDP database. J Peripher Nerv Syst. 2020;11:152‐161. doi:10.1111/jns.12378.
Capodivento G, De Michelis C, Carpo M, et al. CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS. J Neurol Neurosurg Psychiatry. 2021;92:303‐310. doi:10.1136/JNNP‐2020‐324445.

Keywords: biomarker; chronic inflammatory demyelinating polyradiculoneuropathy; outcome measures; prognosis; somatosensory evoked potentials

Date Created: 20240812 Date Completed: 20241008 Latest Revision: 20241107

20241108

10.1002/mus.28234

39132869